Recently, Howard et al [19] used such nanoparticles conjugated with siRNA specific to the BCR/ABL-1 junction sequence and found 90% reduced expression of BCR/ABL-1 leukemia fusion protein in K562 (Ph(+)) cells. The gene discussed is BCR; the disease is leukemia.